Natural shield against rare genetic disease: The miraculous compound in broccoli protects nerve cells

There has been an exciting development in the medical world regarding Friedreich's ataxia (FA), a rare genetic disorder that gradually destroys the central nervous system and deprives children of their ability to walk, speak and muscle control. The study conducted by researchers at Swinburne University in Australia revealed that the natural "sulforaphane" molecule found in high amounts in broccoli can compensate for protein deficiency, which is the main cause of the disease.

The data obtained against this neurodegenerative disease, which currently has no definitive treatment and significantly shortens the lifespan of patients, opens the door to an accessible treatment, especially for pediatric patients.

In Friedreich's ataxia disease, due to a genetic mutation, the "frataxin" protein, which is critical for the survival of nerve cells in the brain and spinal cord, is not produced in sufficient quantities. This causes cellular energy to be depleted and nerve tissues to die over time.

Assoc. Dr. The research team, led by Faith Kwa, proved that sulforaphane obtained from broccoli increases frataxin protein levels at the cellular level. Researchers emphasized that the compound not only completes the missing protein, but also provides multifaceted protection by preventing inflammation and cellular stress in nerve cells.

Assoc. Prof. stated that one of the most devastating aspects of the disease is that it begins in childhood. Dr. Kwa pointed out that there is no specific treatment protocol approved for pediatric patients today.

"Friedreich's ataxia is a cruel disease that gradually takes away from a child the ability to play, walk and move independently. The natural sulforaphane compound directly targets the root biological cause of the disease, while offering a cheap and safe treatment option that is easily accessible to families around the world," Kwa said.

The fact that the safety record of sulforaphane on human health has already been proven and the commercial availability of purified bioactive forms greatly accelerates the process of licensing a potential drug and reaching the patient.

The Swinburne University research team has begun seeking financial support for large-scale clinical trials that will test these successful results obtained in the laboratory environment directly on patients. Experts noted that if the experiments are successful, the quality of life and motor functions can be significantly preserved for thousands of children struggling with this rare disease.